Abstract
In end-stage heart failure the expression of different myocardial regulatory proteins involved in the β-adrenergic cAMP signalling pathway is altered. The downregulation of β1-adrenoceptors and their uncoupling from the effector as well as an increased expression of the inhibitory GTP-binding protein seem to be the most important alterations. Since catecholamine levels are elevated in these patients and since some alterations can be ‘restored’ after treatment with β-adrenoceptor antagonists it was hypothesized that excessive β-adrenergic stimulation could be involved in these alterations.
In this article the changes of β-adrenergic receptors, GTP-binding proteins, sarcoplasmic reticulum Ca2+-ATPase and of phospholamban found in heart failure are addressed with its possible therapeutic implications.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Bristow MR, Hershberger RE, Port JD, Minobe W, Rasmussen R: β1-and β2-adrenergic receptor-mediated adenylate cyclase stimulation in nonfailing and failing human ventricular myocardium. Mol Pharm 35: 295–303, 1989
Daly PA, Sole MJ: Myocardial catecholamines and the pathophysiology of heart failure. Circulation 82(suppl 1): I–35–143, 1990
Schmitz W, Scholz H, Erdmann E: Effects of alpha- and beta-adrenergic agonists, phosphodiesterase inhibitors and adenosine on isolated human heart muscle preparations. Trends Pharmacol Sci 8: 447–450, 1987
Eschenhagen T: G proteins and the heart. Cell Bioi Int 17(8): 723–749, 1993
Bristow MR, Anderson FL, Port DP, Skerl L, Hershberger KS, Larabee P, O Connell JB, Reniund DG, Volkman K, Murray J, Feldman AM: Differences in b-adrenergic neuroeffector mechanisms in ischemic versus idiopathic dilated cardiomyopathy. Circulation 84: 1024–1039, 1991
Böhm M, Gierschik P, Jakobs K-H, Pieske B, Schnabel P, Ungerer M, Erdmann E: Increase of Giα in human hearts with dilated but not ischemic cardiomyopathy. Circulation 82: 1249–1265, 1990
Brodde OE: β1- and β2-adrenoceptors in the human heart: Properties, function, and alterations in chronic heart failure. Pharmacol Rev 43: 203–242, 1991
Steinfath M, Geertz B, Schmitz W, Scholz H, Haverich A, Beil I, Hanrath P, Reupcke C, Sigmund M, Lo HB: Distinct down-regulation of cardiac β1- and β2-adrenoceptors in different human heart diseases. Naunyn-Schmiedeberg’s Arch Pharmacol 343: 217–220, 1991
Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L: Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation 82: 1730–1736, 1990
Ungerer M, Bohm M, Elce JS, Erdmann E, Lohse MJ: Altered expression of 13adrenergic receptor kinase and β1-adrenergic receptors in the failing human heart. Circulation 87: 454–463, 1993
Linder ME, Gilman AG: G proteins. Scientific American July 1992: 36–43
Yatani A, Okabe K, Polakis P, Halenbeck R, McCormick F, Brovvn AM: ras p21 and GAP inhibit coupling of muscarinic receptors to atrial K+ channels. Cell 61: 769–776, 1990
Fleming JW, Wisler PL, Watanabe AM: Signal transduction by G proteins on cardiac tissues. Circulation 85: 420–433, 1992
Brown AM: A cellular logic for G-protein coupled ion channel pathways. FASEB J 5: 2175–2179, 1991
Katz AM: Physiology of the heart. 2nd ed.. Raven Press, New York, 1992
Feldman MD, Copelas L, Gwathmey JK, Phillips P, Warren SE, Schoen FJ, Grossman W, Morgan JP: Deficient production of cyclic AMP: pharmacologic evidence of an important cause of contractile dysfunction in patients with endstage heart failure. Circulation 75: 331–339, 1987
Feldman AM, Cates AE, Veazey WB, Hershberger RE, Bristow MR, Baughman KL; Baumgartner WA, van Dop C: Increase in the 40,000-mol wt pertussis toxin substrate (G-protein) in the failing human heart. J Clin Invest 82: 189–197, 1988
Schnabel P, Böhm M, Gierschik P, Jakobs KH, Erdmann E: Improvement of cholera toxin-catalysed ADP-ribosylation by endogenous ADP-ribosylation factor from bovine brain provides evidence for an unchanged amount of Gsα in failing human myocardium. J Mol Cell Cardiol 22: 73–82, 1990
Neumann J, Schmitz W, Scholz H, von Meyerinck L, Döring V, Kalmár P: Increase of myocardial Gi-proteins in human heart failure. Lancet II: 936–937, 1988
Böhm M, Eschenhagen T, Gierschik P, Larisch K, Lensche H, Mende U, Schmitz W, Schnabel P, Scholz H, Steinfath M, Erdmann E: Radioimmunological quantification of Gi alpha in right and left ventricles from patients with ischaemic and dilated cardiomyopathy and predominant left ventricular failure. J Mol Ceil Cardiol 26: 133–149, 1994
Eschenhagen T, Mende U, Nose M, Schmitz W, Scholz H, Haverich A, Hirt S, Doring V, Kalmár P, Höppner W, Seitz HJ: Increased messenger RNA level of the inhibitory G-protein a subunit Giα-2 in human end-stage heart failure. Circ Res 70: 688–696, 1992
Mende U, Eschenhagen T, Geertz B, Schmitz W, Scholz H, Schulte am Esch J, Sempell R, Steinfath M: Isoprenaline-induced increase in the 40/41 kDa pertussis toxin substrates and functional consequences on contractile response in rat heart. Naunyn-Schmiedeberg’s Arch Pharmacol 345: 44–50, 1992
Eschenhagen T, Mende U, Diederich M, Nose M, Schmitz W, Scholz H, Schulte am Esch J, Warnholtz A, Schöfer H: Long-term β-adrenoceptor mediated upregulation of Giα and Goα mRNA levels and pertussis toxin-sensitive guanine nucleotide-binding proteins in rat heart. Mol Pharm 42: 773–783, 1992
Müller FU, Boheler KR, Eschenhagen T, Schmitz W, Scholz H: Isoprenaline stimulates gene transcription of the inhibitory G-protein α-subunit Giα-2 in rat heart. Circ Res 72: 696–700, 1993
Motomura S, Deighton NM, Zerkowski HR, Doetsch N, Michel MC, Brodde OE: Chronic beta 1-adrenoceptor antagonist treatment sensitizes beta 2-adrenoceptors, but desensitizes M2-muscarinic receptors in the human right atrium. Br J Pharmacol 101 (2): 363–369, 1990
Jakob H, Sigmund M, Beck F, Hanrath P, Eschenhagen T, Geertz B, Scholz H, Steinfath M: Reduction of Giα in myocardial biopsies of patients with heart failure under metoprolol treatment. Circulation 90: 1-413, 1994
Eschenhagen T, Mende U, Nose M, Schmitz W, Scholz H, Warnholtz A, Wustel JM: Isoprenaline-induced increase in mRNA levels of inhibitory G-protein α-subunits in rat heart. Naunyn-Schmiedeberg’s Arch Pharmacol 343:609–615, 1991
Müller FU, Eschenhagen T, Reidemeister A, Schmitz W, Scholz H: In vivo β-adrenergic stimulation leads to biphasic regulation of Giα-2 gene transcriptional activity in rat heart. J Mol Cell Cardiol 26: 869–875, 1994
Gwathmey JK, Copelas L, Makinnon R, Shoen FJ, Feldman MD, Grossman W, Morgan JP: Abnormal intracellular calcium handling in myocardium from patients with end-stage heart failure. Circ Res 61: 70–76, 1987
Limas CJ, Olivari M-T, Goldenberg TB, Benditt DG, Simon A: Calcium uptake by cardiac sarcoplasmic reticulum in human dilated cardiomyopathy. Cardiovasc Res 21: 601–605, 1987
Movsesian MA, Bristow MR, Krall J: Calcium uptake by cardiac sarcoplasmic reticulum from patients with dilated cardiomyopathy. Circ Res 65: 1141–1144, 1989
Movsesian MA, Colyer J, Wang JH, Krall J: Phospholamban-mediated stimulation of Ca2+ uptake in cardiac sarcoplasmic reticulum from normal and failing human hearts. J Clin Invest 85: 1698–1702, 1990
Brandl CJ, Green NM, Korczak B, MacLennan DH: Two Ca2+-AT-Pase genes: homologies and mechanistic implications of deduced amino acid sequences. Cell 44: 597–607, 1986
Burk SE, Lytton J, MacLennan DH, Shull GE: cDNA cloning, functional expression, and mRNA tissue distribution of a third organellar Ca2+ pump. J Biol Chem 264: 18561–18568, 8919
MacLennan DH, Brandle CH, Korczak B, Green NM: Amino-acid sequence of a Ca2+ Mg2+-dependent ATPase from rabbit muscle sarcoplasmic reticulum, deduced from ist complementary DNA sequence. Nature 316: 696–700, 1985
Jones LR: Sarcolemmal enzymes mediating β-adrenergic effects in the heart. In: F. A. Bronner, A. E. Shamoo, AE (eds). Current topics in membranes and transport; regulation of calcium transport across muscle membranes. Academic Press, New York, 1985, pp 11–41
Mercadier J-J, Lompré AM, Duc P, Boheler KR, Frays J-P, Wisnewsky C, Allen PD, Komajda M, Schwartz K: Altered sarcoplasmic reticulum Ca2+ ATPase gene expression in the human ventricle during end-stage heart failure. J Clin Invest 85: 305–309, 1990
Arai M, Alpert NR, MacLennan DH, Barton P, Periasamy M: Alterations in sarcoplasmic reticulum gene expression in human heart failure: a possible mechanism for alterations in systolic and diastolic properties of the failing myocardium. Circ Res 72: 463–469, 1993
Movsesian MA, Karimi M, Green K, Jones LR: Ca2+-transporting ATPase, phospholamban and calsequestrin levels in nonfailing and failing human heart. Circulation 90: 653–657, 1994
Hasenfuss G, Reinicke H, Studer R, Meyer M Pieske B, Holtz J, Holubarsch C, Posival H, Just H, Drexler H: Relation between myocardial function and expression of sarcoplasmic reticulum Ca2+-ATPase in failing and nonfailing myocardium. Circ Res 75: 434–442, 1994
Luo W, Grupp IL, Harrer J, Ponniah S, Grupp G, Duffy JJ, Doetschman T, Kranias EG: Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of β-agonist stimulation. Circ Res 75: 401–409, 1994
Danielsen W, von der Leyen H, Meyer W, Neumann J, Schmitz W, Scholz H, Starbatty J, Stein B, Döring V, Kalmár P: Basal and isoprenaline-stimulated cAMP content in failing versus nonfailing human cardiac preparations. J Cardiovasc Pharmacol 14: 171–173, 1989
Böhm M, Reiger B, Schwinger RH, Erdmann E: cAMP concentrations, cAMP dependent protein kinase activity, and phospholamban in nonfailing and failing myocardium. Cardiovasc Res 28(11): 1713–1719, 1994
Shenolikar S, Nairn AC: Protein phosphatases: recent progress. In: P. Greengard and G. A. Robison (eds). Advances in second messenger and phosphoprotein research. Raven Press, New York, 1991, pp 1–121
Neumann J, Eschenhagen T, Jones LR, Linck B, Schmitz W, Scholz H, Zimmermann N: Increased expression of cardiac phosphatases in patients with endstage heart failure. 1995 (submitted)
Deighton NM, Motomura S, Borquez D, Zerkowski H-R, Doetsch N, Brodde O-E: Muscarinic cholinoceptors in the human heart: demonstration, subclassification, and distribution. Naunyn-Schmiedebergs’s Arch Pharmacol 341: 14–21, 1990
Kohl C, Schmitz W, Scholz H: Positive inotropic effect of carbachol and inositol phosphate levels in mammalian atria after pretreatment with pertussis toxin. J Pharmacol Exp Ther 254: 894–899, 1990
Brückner R, Fenner A, Meyer W, Nobis T-M, Schmitz W, Scholz H: Cardiac effects of adenosine and adenosine analogs in guinea-pig atrial and ventricular preparations: evidence against a role of cyclic AMP and cyclic GMP: J Pharmacol Exp Ther 234: 766–774, 1985
Brown AM, Birnbaumer L: Ionic channels and their regulation by G protein subunits. Annu Rev Physiol 52: 197–213, 1990
Gilman AG: G proteins and dual control of adenylate cyclase. Cell 36: 577–579, 1984
Gupta RC, Neumann J, Boknik P, Watanabe AM: M2-specific muscarinic cholinergic receptor-mediated inhibition of cardiac regulatory protein phosphorylation. Am J Physiol 266: H1138–H1144, 1994
Neumann J, Boknik P, Bodor GS, Jones LR, Schmitz W, Schoiz H: Effects of adenosine receptor and muscarinic cholinergic receptor agonists on cardiac protein phosphorylation. J Pharmacol Exp Ther 269:1310–1318: 1994
Mery PF, Lohmann SM, Walter U, Fischmeister R: Ca2+ current is regulated by cyclic GMP-dependent protein kinase in mammalian cardiac myocytes. Proc Natl Acad Sci USA 88: 1197–1201, 1991
Mery PF, Pavoine C, Belhassen L, Pecker F, Fischmeister R: Nitric oxide regulates cardiac Ca2+ current. Involvement of cGMP-inhibited and cGMP-stimulated phosphodiesterases through guanylyl cyclase activation. J Biol Chem 268: 26286–26295, 1993
Ahmad Z, Green FJ, Subuhi HS, Watanabe AM: Autonomic regulation of type 1 protein phosphatase in cardiac muscle. J Biol Chem 264:3859–3863, 1989
Neumann J, Kaspareit G, Scholz H: Fluoride ion attenuates the negative inotropic effects of muscarinic M2 and adenosine receptor agonists. Eur J Pharmacol, in press, 1995
Herzig S, Meier A, Pfeiffer M, Neumann J: Stimulation of protein phosphatases as a mechanism of the muscarinic-receptor-mediated inhibition of cardiac L-type Ca2+ channels. Pflüger’s Arch — Eur J Physiol 429: 531–538, 1995
Böhm M, Ungerer M, Erdmann E: Adenosine receptors in the human heart: Pharmacological characterization in nondiseased and cardiomyopathic tissue. Drug Develop Res 28: 268–276, 1993
von der Leyen H, Mende U, Meyer W, Neumann J, Nose M, Schmitz W, Scholz H, Starbatty J, Stein B, Wenzlaff H, Doring V, Kalmár P, Haverich A: Mechanism underlying the reduced positive inotropic effects of the phosphodiesterase inhibitors pimobendan, adibendan and saterinone in failing as compared to nonfailing human cardiac muscle preparations. Naunyn-Schmiedeberg’s Arch Pharmacol 344: 90–100, 1991
Schmitz W, Eschenhagen T, Mende U, Muller FU, Neumann J, Scholz H: Phosphodiesterase inhibition and positive inotropy in failing human myocardium. In: G. Hasenfuss, Ch. Holubarsch, H. Just and N. R. Alpert (eds). Cellular and Molecular Alterations in the Failing Human Heart. Steinkopff Verlag, Darmstadt, 1992, pp 65–71
Bethke T, Klimkievvicz A, Kohl C, von der Leyen H, Mehl H, Mende U, Meyer W, Neumann J, Schmitz W, Scholz H, Starbatty J, Stein B, Wenzlaff H, Döring V, Kalmar P, Haverich A: Effects of isomazole on force of contraction and phosphodiesterase isoenzymes in nonfailing and failing human hearts. J Cardiovasc Pharmacol 18: 386–397, 1991
Bethke T, Eschenhagen T, Klimkie\,vicz A, Kohl C, von der Leyen H, Mehl H, Mende U, Neumann J, Rossvvag S, Schmitz W, Scholz H, Starbatty J, Stein B, Wenzlaff H, Döring V, Kalmár P, Haverich A: Phosphodiesterase inhibition by enoximone in preparations from failing and nonfailing human hearts. Arzneimittel Forsch 42: 437–445, 1992
Levine TB, Francis GS, Goldsmith SR, Simon AB, Cohn JN: Activity of the sympathetic nervous system and renin-angiotensin system assesed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure. Am J Cardiol 49: 1659–1666, 1982
Gage J, Rutman H, Lucido D, LeJemtel TH: Additive effects of dobutamine and amrinone on myocardial contractility and ventricular performance in patients with severe heart failure. Circulation 74: 367–373, 1986
Colucci WS: Observations on the intracoronary administration of milrinone and dobutamine to patients with congestive heart failure. Am J Cardiol 63: 17–22, 1989
Gilbert EM, Port JD, Hershberger RE, Bristow MP: Clinical significance of alterations in the β-adrenergic receptor-adenylate cyclase complex in heart failure. Heart Failure 5: 91–98, 1989
Packer M, Medina M, Yushak M: Hemodynamic and clinical limitations of longterm inotropic therapy with amrinone in patients with severe chronic heart failure. Circulation 70: 1038–1047, 1984
Uretsky BF, Jessup M, Konstam MA, Dec GW, Leier CV, Benotti J, Muralli S, Herrmann HC, Sandberg JA: Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Circulation 82: 774–780, 1990
The CONSENSUS Trial Study Group: Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316: 1429–1435, 1987
Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, Hendrix GH, Bommer WJ, Elkayam U, Kukin ML, Mallis GI, Sollano JA, Shannon J, Tandon PK, Demets DL: Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 325: 1468–1475, 1991
Packer M: Pathophysiology of chronic heart failure. Lancet 340: 88–92, 1992
Rüegg JC, Solaro RJ: Calcium-sensitizing positive inotropic drugs. In: J.K. Gwathmey, G.M. Briggs and P.D. Allen (eds). Heart Failure: Basic Science and Clinical Aspects. Marcell Dekker, Inc., New York, 1993, pp 457–473
captopril Multicenter Research Group: A placebo-controlled trial of captopril in refractory chronic congestive heart failure. J Am Coll Cardiol 2: 755–763, 1983
The SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325: 293–302, 1991
The SOLVD Investigators: Effect on enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 327: 685–691, 1992
The SAVE Investigators: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 327: 669–677, 1992
The AIRE Investigators: Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 3452: 821–882, 1993
Fowler MB, Laser JA, Hopkins GL, Minobe W, Bristow MR: Assessment of the β-adrenergic receptor pathway in the intact failing human heart: progressive receptor downregulation and subsenssitivity to agonist response. Circulation 74: 1290–1302, 1986
Gilbert EM, Sandoval A, Larrabee P, Reniund DG, O Connell JB, Bristow MR: Lisinopril lowers cardiac adrenergic drive and increases β-adrenoceptor density in the failing human heart. Circulation 88:472–480, 1993
Jakob H, Sigmund M, Eschenhagen T, Mende U, Patten M, Schmitz W, Scholz H, Schulte am Esch J, Steinfath M, Hanrath P, Völker H: Effect of captopril on myocardial β-adrenoceptor density and Giα-proteins in patients with mild to moderate heart failure due to dilated cardiomyopathy. Eur J Clin Pharmacol 47: 389–394, 1994
Hjalmarson A, Waagstein F: New therapeutic strategies in chronic heart failure: Challenge of long-term beta-blockade. Eur Heart J 12(Suppl F): 63–69, 1991
Eichhorn EJ: The paradox of beta-adrenergic blockade for the management of congestive heart failure. Am J Med 92:527–538, 1992
Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group: Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, Gilbert EM, Johnson MR, Goss FG, Hjalmarson A: Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 342:1441–1446, 1993
Fisher ML, Gottlieb SS, Plotnick GD, Greenberg NL, Patten RD, Bennett SK, Hamilton BP: Beneficial effects of metoproiol in heart failure associated with coronary artery disease: a randomized trial. J Am Coll Cardiol 23: 943–950, 1994
A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. Circulation 90(4): 1765–1773, 1994
Bristow MR, O Connell JB, Gilbert EM, French WJ, Leatherman G, Kantrowitz NE, Orie J, Smucker ML, Marshall G, Kelly P et al. for the Bucindolol Investigators: Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Circulation 89(4): 1632–1642, 1994
Eichhorn EJ, Heesch CM, Risser RC, Marcoux L, Hatfield B: Predictors of systolic and diastolic improvement in patients with dilated cardiomyopathy treated with metoprolol. J Am Coll Cardiol 25(1): 154–162, 1995
Eichhorn EJ, McGhie I, Bedotto JB, Corbett JR, Malloy CR, Hatfield BA, Deitchman D, Willard JE, Grayburn PA: Effects of bucindolol on neurohumoral activation in congestive heart failure. Am J Cardiol 676: 67–73, 1991
Chadda K, Goldstein S, Byington R, Curb JD: Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation 73: 503–510, 1986
Katz AM: Cell death in the failing heart: role of an unnatural growth response to overload. Clin Cardiol, in press, 1995
Müller FU, Bokník P, Horst A, Knapp J, Linck B, Schmitz W, Vahlensieck U, Böhm M, Deng MC, Scheld HH: The cAMP response element binding protein (CREB) is expressed and phosphorylated in the human heart. Circulation, in press, 1995
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Kluwer Academic Publishers
About this chapter
Cite this chapter
Schmitz, W., Boknik, P., Linck, B., Müller, F.U. (1996). Adrenergic and muscarinic receptor regulation and therapeutic implications in heart failure. In: Lamers, J.M.J., Verdouw, P.D. (eds) Biochemistry of Signal Transduction in Myocardium. Developments in Molecular and Cellular Biochemistry, vol 17. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-1275-8_33
Download citation
DOI: https://doi.org/10.1007/978-1-4613-1275-8_33
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-8544-1
Online ISBN: 978-1-4613-1275-8
eBook Packages: Springer Book Archive